# Development of a blood test for uterine sarcoma—Diagnosis and monitoring (DOORS-D and DOORS-M) studies

**Authors:** Anna Casey, Rebecca Allsopp, Jacqui Shaw, Caroline Cowley, Elizabeth Stannard, Yvette Griffin, Indrajeet Das, Marc Wadsley, Natalie Darko, Esther L. Moss, Mohamed Gouda, Mohamed Gouda, Mohamed Gouda

PMC · DOI: 10.1371/journal.pone.0339336 · PLOS One · 2026-02-17

## TL;DR

This study aims to develop a blood test using ctDNA to diagnose and monitor uterine sarcomas, helping to distinguish them from fibroids and improve patient outcomes.

## Contribution

The study introduces a novel approach using ctDNA and large language models for diagnosing and monitoring uterine sarcomas.

## Key findings

- ctDNA analysis will help differentiate uterine sarcomas from fibroids.
- Longitudinal blood sampling will aid in monitoring sarcoma progression.
- Patient perspectives will inform the development of the diagnostic test.

## Abstract

Uterine sarcomas can be difficult to differentiate from uterine fibroids due to many shared symptoms and imaging features, which can result in delayed or missed diagnosis, or over treatment. The ‘Development of a blood test for uterine Sarcoma – Diagnosis’ (DOORS-D) (ISRCTN14800787) and ‘Development of a blood test for uterine Sarcoma – Monitoring’ (DOORS-M) (ISRCTN14174468) studies aim to explore the role for circulating tumour DNA (ctDNA) to diagnose and to monitor uterine sarcomas. DOORS-D will recruit patients who have a suspected uterine sarcoma or large fibroid and are due to undergo surgery (hysterectomy or myomectomy) for a blood sample prior to surgery whereas DOORS-M will recruit patients who have been diagnosed with a uterine sarcoma in the previous 10 years for longitudinal blood sampling every 3–6 months over the course of the study. Information will be collated on patient characteristics and symptoms, tumour characteristics and diagnostic imaging, with representative images selected and analysed using large language models. Analysis of genomic/methylation profile of ctDNA samples collected from DOORS-M will be used to design a ctDNA-based ‘test’. Analysis of the samples collected from the participants recruited to the DOORS-D study will enable the accuracy of the ‘test’ to differentiate uterine sarcomas from fibroids to be determined. In addition, the opinions of patients with a suspected or confirmed sarcoma will be explored through semi-structured qualitative interviews. Purposeful recruitment strategy will ensure that the experiences of women from diverse socioeconomic, cultural and ethnic backgrounds are included. The results of the studies will be shared through conference presentations and peer-reviewed publications.

## Linked entities

- **Diseases:** uterine sarcoma (MONDO:0005210)

## Full-text entities

- **Genes:** WFDC2 (WAP four-disulfide core domain 2) [NCBI Gene 10406] {aka BENP, EDDM4, HE4, WAP5, dJ461P17.6}, BRCA1 (BRCA1 DNA repair associated) [NCBI Gene 672] {aka BRCAI, BRCC1, BROVCA1, FANCS, IRIS, PNCA4}, BRCA2 (BRCA2 DNA repair associated) [NCBI Gene 675] {aka BRCC2, BROVCA2, FACD, FAD, FAD1, FANCD}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, ALK (ALK receptor tyrosine kinase) [NCBI Gene 238] {aka ALK1, CD246, NBLST3}, MUC16 (mucin 16, cell surface associated) [NCBI Gene 94025] {aka CA125}, BRAF (B-Raf proto-oncogene, serine/threonine kinase) [NCBI Gene 673] {aka B-RAF1, B-raf, BRAF-1, BRAF1, NS7, RAFB1}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, PDCD1 (programmed cell death 1) [NCBI Gene 5133] {aka ADMIO4, AIMTBS, CD279, PD-1, PD1, SLEB2}, RB1 (RB transcriptional corepressor 1) [NCBI Gene 5925] {aka OSRC, PPP1R130, RB, p105-Rb, p110-RB1, pRb}, LDHC (lactate dehydrogenase C) [NCBI Gene 3948] {aka CT32, LDH3, LDHX}
- **Diseases:** smooth muscle tumour (MESH:D018235), M (MESH:C566367), Uterine fibroids (MESH:D007889), ESS (MESH:D018203), peritoneal or lymph node metastases (MESH:D008207), peritoneal (MESH:D010538), CRF (MESH:C565541), menorrhagia (MESH:D008595), irregular uterine bleeding (MESH:D014592), endometrial cancer (MESH:D016889), Sarcoma (MESH:D012509), distress (MESH:D012128), pelvic mass (MESH:C536030), Lynch syndrome (MESH:D003123), haemorrhage (MESH:D006470), obesity (MESH:D009765), DOORS-M (MESH:D013736), mesenchymal tumours (MESH:D008637), DOORS-D (MESH:D001523), chromosomal abnormalities (MESH:D002869), uterine cancer (MESH:D014594), Tumour (MESH:D009369), LMS (MESH:D007890), retroperitoneal sarcomas (MESH:D012186), STUMP (MESH:D019042)
- **Chemicals:** formalin (MESH:D005557), Esther (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12912590/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12912590/full.md

## References

49 references — full list in the complete paper: https://tomesphere.com/paper/PMC12912590/full.md

---
Source: https://tomesphere.com/paper/PMC12912590